Brief: Zynerba Pharmaceuticals Announces New Two-Year Data From Open Label Extension Of The Phase 2 Fab-C Trial In Patients With Fragile X
26/05/2020 12:44
May 26 (Reuters) - Zynerba Pharmaceuticals Inc ZYNE.O :
* ZYNERBA PHARMACEUTICALS ANNOUNCES NEW TWO-YEAR DATA FROM
OPEN
LABEL EXTENSION OF THE PHASE 2 FAB-C TRIAL IN PATIENTS WITH
FRAGILE X AT 2020 AMERICAN ACADEMY OF NEUROLOGY (AAN) SCIENCE
HIGHLIGHTS VIRTUAL SESSION
* ZYNERBA PHARMACEUTICALS INC - TOP LINE RESULTS OF PIVOTAL
CONNECT-FX TRIAL EXPECTED LATE IN Q2 OF 2020
* ZYNERBA PHARMA - ROBUST RESPONSE SUSTAINED THROUGH TWO
YEARS OF
TREATMENT WITH ZYGEL IN PATIENTS FROM PHASE 2 FAB-C TRIAL
* ZYNERBA PHARMA- DATA SHOW STATISTICALLY SIGNIFICANT
IMPROVEMENTS
FROM BASELINE THAT WERE OBSERVED AT WEEK 12 WERE SUSTAINED
Source text for Eikon: ID:nGNX3Rcxsx
Further company coverage: ZYNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zynerba Pharmaceuticals
See all newsBrief: Harmony Biosciences Completes Acquisition Of Zynerba Pharmaceuticals
Brief: Harmony Biosciences Announces Extension Of Tender Offer To Acquire Zynerba Pharmaceuticals, Inc.
Brief: Zynerba Pharmaceuticals Presents Positive Data From Phase 2 Inspire Trial
U.S. RESEARCH ROUNDUP-Easterly Government Properties, Visa, Zynerba Pharmaceuticals
Zynerba Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary